Cardiovascular Disease

FOURIER-OLE Shows Benefits of Reducing LDL-C Levels

LDL-C image

How low can you go? The lower the better, at least when it comes to low-density lipoprotein cholesterol (LDL-C). That’s according to new findings from the FOURIER-OLE study, which found the lowest rates of cardiovascular disease among individuals with the lowest LDL-C levels.

High LDL-C is a well-known cardiovascular disease risk factor, but cholesterol-lowering drugs like statins have been remarkably successful in helping people reduce their lipid levels. Currently, optimal LDL-C is considered to be under 100 mg/dL.

In FOURIER-OLE, researchers examined how reducing LDL-C to different levels below the optimal threshold impacted cardiovascular disease incidence. They examined a subset of 6,635 participants from the FOURIER study, which itself had 27,564 individuals who received either a placebo or Amgen’s cholesterol-lowering drug Repatha (evolocumab).

FOURIER-OLE researchers followed this subset of individuals for an additional five years to determine the relationship between LDL-C levels and major cardiovascular events, finding that:

  • The rates of cardiovascular events tended to be lowest for those with the lowest LDL-C levels (<20 mg/dL).
  • There was no statistically significant association between lower LDL-C levels and increased risk of safety outcomes from use of Repatha – which had been an issue in a recent reanalysis of FOURIER study data. 
  • Despite lowering cardiovascular events, Repatha use had no statistically significant impact on all-cause mortality.

The study and related Cardiology Twitter chatter raise a number of questions: 

  • Should established clinical guidelines for LDL-C be lowered even further to spread the benefits of lipid-lowering drugs to more individuals?
  • If so, what would be the cost of such an expansion? 
  • How concerning is FOURIER-OLE’s lack of an impact on all-cause mortality? 

The same chatter also revealed some lingering misconceptions about Repatha’s cost, which most seem to believe is still $14,000 annually. However, Repatha was reduced by 60% to $6,600 in 2018, bringing it in line with the standard of care.

The Takeaway

In addition to reinforcing the benefits of lipid-lowering drugs, the new FOURIER-OLE findings revive the debate over the cost-effectiveness of population-based cardiovascular interventions. Sure, lower is better – but at what cost?

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

This content is exclusive to subscribers

Log in or join by entering your email below.

Completely free. Every Monday and Thursday.

CW Phone Square

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!